secwatch.observer — SEC 8-K summary
======================================

Issuer:     GUIDED THERAPEUTICS INC (GTHP)
CIK:        0000924515
Form:       8-K
Filed at:   2022-09-15T23:59:59+00:00
Accession:  0001477932-22-006945
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guided Therapeutics closes $3.3M bridge financing, exchanges Auctus debt, targets FDA study completion
--------------------------------------------------------------------------------

- Raised ~$3.3M via 6.6M shares at $0.50 each, plus four-year warrants for 6.6M shares at $0.50 and 6.6M at $0.65.
- Auctus exchanged $1.06M debt and 8.78M warrants for $1.95M in units (3.9M shares, 3.9M warrants at $0.50 and $0.65); residual $490K debt over 18 months.
- Net proceeds ~$3.2M; primary use to fund clinical study data for FDA approval of LuViva Advanced Cervical Scan, also support international sales and reduce debt.
- Stockholders' equity nearly break-even; Company to withdraw S-1/A for Nasdaq uplist and reapply when market conditions improve.
- Investors include board members Richard Blumberg, Michael James, John Imhoff.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/924515/000147793222006945/0001477932-22-006945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/924515/000147793222006945/gthp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-22-006945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer